BioCentury
ARTICLE | Financial News

Regado to raise $20 million in private placement

February 1, 2014 1:35 AM UTC

Regado Biosciences Inc. (NASDAQ:RGDO) plans to raise $20 million through the sale of 4 million shares at $5 in a private placement to new and existing investors. Cowen and BMO are placement agents. Regado's REG1 Anticoagulation System is in the Phase III REGULATE-PCI trial to treat acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI). REG1 is composed of pegnivacogin ( RB006), a pegylated, single-stranded RNA aptamer that binds to Factor IXa, and anivamersen ( RB007), a complementary single-stranded RNA containing a 15-nucleotide sequence that binds to and neutralizes pegnivacogin. ...